Comorbidities in Multiple Myeloma

Size: px
Start display at page:

Download "Comorbidities in Multiple Myeloma"

Transcription

1 Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014

2

3 Disclosures Advisory board: Janssen, Celgene Speaker s honoraria: Janssen, Celgene, Novartis 3

4 Male patient, 76 y Medical history: arterial hypertension total knee replacement Medication: amlodipine 5 mg/d Current problem: newly diagnosed MM, IgG kappa CRAB: anemia, pathological rib fracture Patient is active and independent Which treatment would you prefer: 1. VMP twice weekly 2. VMP weekly 3. VMPT 4. MPT 5. Lenalidomide-dexamethasone

5 Male patient, 72 y Medical history: coronary bypass COPD GOLD II chronic atrial fibrillation Medication: dabigatran, atenolol, perindopril Current problem: newly diagnosed MM, IgG kappa CRAB: anemia, pathological vertebral fracture Patient has mild/moderate dyspnea Which treatment would you prefer: 1. VMP twice weekly 2. VMP weekly 3. VMPT 4. MPT 5. Lenalidomide-dexamethasone

6 Treatment optimization Aim: to deliver effective treatment without excessive toxicity Efficacy Toxicity Risk of undertreatment: early relapse Risk of overtreatment: early treatment discontinuation

7 Comorbidities It is the concurrent presence of two or more medically diagnosed diseases in the same individual, with the diagnosis of each contributing disease based on established, widely recognized criteria. between 65 and 80y: one third has at least one comorbidity 80 y: up to 70% of the population has at least one comorbidity men women Fried et al, J Gerontol 2004;59:255

8 Type of comorbidities Chronic diseases mental illness cardiac disease (e.g. cardiac failure, arhytmia) chronic respiratory disease (e,g, COPD) hepatic disease kidney disorders (e.g. renal insufficiency) diabetes vascular disease musculoskeletal disorders peripheral nerve disorders acute intercurrent diseases another invasive malignancy * examples for multiple myeloma

9 disease-related adverse events as comorbidities pathological fracture, spinal cord compression, hypercalcemia renal failure infection

10 Treatment-related adverse events More treatment discontinuation in patients > 75y Palumbo et al, Blood 2011;118:4519

11 Impact of cardiac, infective and gastrointestinal AEs on survival All patients Treatment subgroups HR (95% CI ) P value n = 1435 All 2.53 (1.75 to 3.64) <0.001 MP 1.46 (0.59 to 3.63) 0.41 MPT 2.96 (1.71 to 5.15) <0.001 VMP 2.73 (1.03 to 7.24) 0.04 VMPT/VTP 2.77 (1.18 to 6.51) , Higher mortality in patients without cardiac, infective or GI AEs Higher mortality in patients with cardiac, infective or GI AEs Bringhen et al. Haematologica 2013;98:980

12 Aiming too high in the very elderly MPR a MP Discontinuation rate b years of age 17% 10% > 75 years of age 34% 16% Cumulative dose intensity c years of age 88% 97% > 75 years of age 56% 97% a MPR includes MPR-R and MPR for the initial 9 cycles. b Discontinuation due to AEs or withdrawal of consent c Cumulative dose intensity of melphalan and lenalidomide/placebo Palumbo A, et al. Blood. 2010;116: Abstract 622.

13 How to assess comorbidities? Clinical judgement driven by clinical experience Pro: fast Con: measurement can be time- and circumstance-dependent Global scores for health assessment: Karnofsky Performance Status ECOG/WHO score Specific scores: for transplant candidates: HCT-CI (Charlson, Sorror) for non-transplant candidates: comprehensive geriatric assessment (cga)

14 Scores for overall health evaluation ECOG/0WHO/Zubrod performance score Score Description 0 asymptomatic (Fully active, able to carry on all predisease activities without restriction) 1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) 2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours) 3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours) 4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair) 5 death

15 Scores for overall health evaluation Karnofsky Performance Score Score Description 100% normal, no complaints or signs of disease 90% normal activity, few symptoms or signs 80% normal activity with some difficulty, symptoms or signs 70% caring for self, not capable of normal activity or work 60% requires some help, can take care of most personal requirements 50% requires help often, requires frequent medical care 40% disabled, requires special care and help 30% severely disabled, hospital admission indicated but no risk of death 20% very ill, urgently requiring admission, requires supportive measurements or treatment 10% moribund, rapidly progressive fatal disease process 0% death Karnofsky DA et al. 1949

16 Specific comorbidity scores for myeloma n = 466 MM patients comorbidities measured: Karnofsky Performance Scale kidney function (egfr) respiratory function (FEV1/FVC) Kleber et al. Clin Myeloma, Lymphoma & Leukemia 2013;13:541

17 Specific comorbidity scores for myeloma combination with ISS and age Kleber et al. Clin Myeloma, Lymphoma & Leukemia 2013;13:541

18 Disability Disability is defined as difficulty or dependency in carrying out activities essential to independent living, including essential roles, tasks needed for self-care and living independently in a home, and desired activities important to one s quality of life Disability can be measured with: -ADL*: e.g. dressing, eating, bathing, -IADL**: e.g. using a phone, preparing a meal, *ADL: activities of daily living **IADL: instrumental activities of daily living Fried et al, J Gerontol 2004;59:255

19 Frailty Frailty can be defined as a physiologic state of increased vulnerability to stressors that results from decreased physiologic reserves, and even dysregulation, of multiple physiologic systems. Clinical symptoms are: weakness, low physical activity, weight loss, poor endurance, slow gait speed 1 Kaplan Meier probability of survival over 12 years, according to baseline health status, for persons 70 years or older (D). 1.Fried et al, J Gerontol 2004;59:255 Rockwood et al. CMAJ DOI: /cmaj Palumbo et al, Blood 2011;118(17):

20 Overlap between comorbidity, frailty, disability Disability Comorbidity 21% 5.7% 46% 27% Frailty Data from the Cardiovascular Health Study (n = 2762 participants > 65y) Fried et al, J Gerontol Med Sci 2001;56A: M146

21 Frail patients with comorbidities are underrepresented in clinical trials (n = 85 clinical trials) The main finding from our study is that older patients are still commonly excluded from clinical trials on hematologic malignancies,,,, Cherubini et al. Haematologica 2013;98:997

22 Multiple myeloma is primarily a disease of the elderly patient patiens (%)

23 An intuitive approach for vulnerable MM patiens Risk factors age over 75 y mild, moderate or severe frailty comorbidities: cardiac/pulmonary/hepatic/renal dysfunction GO-GO MODERATE-GO SLOW-GO no risk factors at least one risk factor at least one risk factor plus occurence of grade 3-4 non-hematol. AE Dose level 0 Dose level - 1 Dose level - 2 Palumbo et al, Blood 2011;118(17):

24 Dose and regimen adjustment according to vulnerability DOSE LEVEL 0 DOSE LEVEL 1 DOSE LEVEL 2 Lenalidomide 25 mg/d d 1-21 / 4 wks 15 mg/d d 1-21 / 4 wks 10 mg/d d 1-21 / 4 wks Thalidomide 100 mg/d 50 mg/d 50 mg/every other day Bortezomib 1.3 mg/m 2 d 1,8,15,22 / 5 wks 1.0 mg/m 2 d 1,8,15,22 / 5 wks 1.3 mg/m 2 d 1,15 / 4 wks Melphalan 0.2 mg/kg/d d 1-4 / 5 wks 0.15 mg/kg d 1-4 / 5 wks 0.10 mg/kg d 1-4 / 5 wks Prednisone 2 mg/kg/d d 1-4 / 5 wks 1.5 mg/kg/d d 1-4 / 5 wks 1 mg/kg/d d 1-4 / 5 wks Palumbo et al N Engl J Med. 2011;364:1046

25 Comprehensive geriatric assessment Functionality: ADL IADL Falls Fatigue: MOB-T Pain: VAS score Mental health: MMSE GDS-4 Nutritional status: MNA-SF Social Status ADL: Activities of Daily Living; IADL: Instrumental Activities of Daily Living, MOB-T: Mobility-Tiredness Test: MMSE: Mini-Mental Status Examination; GDS: Geriatric Depression Score; MNA: Mini-Nutritional Assessment Short Form; VAS: Visual Analogue Scale Kenis et al. Ann Oncol 2013;24:1307

26 n = 1967 cancer patients 70% had a geriatric risk profile (G8 score) in 62% physicians were aware of the geriatric assessment In 52% GA detected unknown geriatric problems In 26% this resulted in a specific geriatric intervention In 25% GA influenced anti-tumoral treatment decision Kenis et al. Ann Oncol 2013;24:1307

27 Larocca et al. ASH 2013 (Abstract 687), oral presentation

28 Larocca et al. ASH 2013 (Abstract 687), oral presentation

29 Larocca et al. ASH 2013 (Abstract 687), oral presentation

30 Larocca et al. ASH 2013 (Abstract 687), oral presentation

31 Larocca et al. ASH 2013 (Abstract 687), oral presentation

32 Larocca et al. ASH 2013 (Abstract 687), oral presentation

33 Larocca et al. ASH 2013 (Abstract 687), oral presentation

34 Overall conclusions Patient-specific characteristics (comorbidities, disability, frailty) should be included in treatment decision A comprehensive geriatric assessment is recommended in the (very) elderly MM patients Patient vulnerability affects treatment adverse events, treatment duration and progressionfree and overall survival Risk-adapted treatment can improve the outcome of the vulnerable MM patient

35 Future: specific biomarkers for aging? Pallis et al. J Geriat Oncol 2014;5:84

36

Risk stratification in the older patient; what are our priorities?

Risk stratification in the older patient; what are our priorities? Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs

More information

Treatment of elderly multiple myeloma patients

Treatment of elderly multiple myeloma patients SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division

More information

TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA

TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment

More information

Geriatrics and Cancer Care

Geriatrics and Cancer Care Geriatrics and Cancer Care Roger Wong, BMSc, MD, FRCPC, FACP Postgraduate Dean of Medical Education Clinical Professor, Division of Geriatric Medicine UBC Faculty of Medicine Disclosure No competing interests

More information

Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant

Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol

More information

Treatment of elderly patients with multiple myeloma

Treatment of elderly patients with multiple myeloma Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact

More information

Disclosures for Alessandra Larocca, MD

Disclosures for Alessandra Larocca, MD Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest

More information

To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors

To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene

More information

Frailty Assessment: Simplifying the Complex

Frailty Assessment: Simplifying the Complex Frailty Assessment: Simplifying the Complex Natalie Sanders, DO Internal Medicine, Geriatrics Rocky Mountain Geriatrics Conference 2017 U N I V E R S I T Y O F U T A H H E A L T H, 2 0 1 7 OBJECTIVES Define

More information

Management of Multiple

Management of Multiple Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive

More information

Disclosures for Palumbo Antonio, MD

Disclosures for Palumbo Antonio, MD Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant

More information

Treatment Strategies for Transplant-ineligible NDMM Patients

Treatment Strategies for Transplant-ineligible NDMM Patients 1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily

More information

COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France

COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,

More information

Stem cell transplantation in elderly, but fit multiple myeloma patients

Stem cell transplantation in elderly, but fit multiple myeloma patients Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM

More information

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India IMPORTANCE OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CANCER IN ELDERLY AN INDIAN PERSPECTIVE Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India INTRODUCTION - Cancer in

More information

CREDIT DESIGNATION STATEMENT

CREDIT DESIGNATION STATEMENT CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance

More information

CME Information LEARNING OBJECTIVES

CME Information LEARNING OBJECTIVES CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)

More information

Cancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka

Cancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise

More information

Geriatric screening tools in older patients with cancer

Geriatric screening tools in older patients with cancer Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential

More information

Multiple Myeloma: Approach to the Elderly

Multiple Myeloma: Approach to the Elderly Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards

More information

Christine Chen Princess Margaret Cancer Centre September 2013

Christine Chen Princess Margaret Cancer Centre September 2013 Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board

More information

Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach

Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper

More information

Myeloma update ASH 2014

Myeloma update ASH 2014 Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible

More information

Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease

Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the

More information

Maintenance therapy after autologous transplantation

Maintenance therapy after autologous transplantation Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation

More information

Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant

Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in

More information

Transplant in MM patients: Early versus late. Mario Boccadoro. Barcelona

Transplant in MM patients: Early versus late. Mario Boccadoro. Barcelona Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus

More information

Multiple Myeloma Updates 2007

Multiple Myeloma Updates 2007 Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from

More information

Novel Combination Therapies for Untreated Multiple Myeloma

Novel Combination Therapies for Untreated Multiple Myeloma Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers

More information

Mayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3

Mayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3 NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather

More information

Assessing older patients with hematological malignancies

Assessing older patients with hematological malignancies Assessing older patients with hematological malignancies Alfonso J. Cruz Jentoft Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid, Spain Is old = frail? 45 days old 2,000 years old 4,600

More information

Induction Therapy & Stem Cell Transplantation for Myeloma

Induction Therapy & Stem Cell Transplantation for Myeloma Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant

More information

New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic)

New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic) New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic) Andrew S. Artz, MD, MS Associate Professor of Medicine Clinical Director, Hematopoietic Cellular Therapy Program University

More information

Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum

Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic

More information

SCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS

SCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS SCALES SCALES SCALES WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? Karen L. Cross, MD, FAAHPM Performance Scales KPS FAST ECOG PPS NYHA MRI ALSFRS PPS = 30, 40, or 50 ECOG = 2, 3, or 4 NYHA

More information

Clinical Case Study Discussion: Maintenance in MM

Clinical Case Study Discussion: Maintenance in MM www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure

More information

Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors

Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones

More information

Consolidation and maintenance therapy for transplant eligible myeloma patients

Consolidation and maintenance therapy for transplant eligible myeloma patients Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University

More information

Progress in Multiple Myeloma

Progress in Multiple Myeloma Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:

More information

Integrating Frailty Screening for Older Patients Diagnosed with Multiple Myeloma

Integrating Frailty Screening for Older Patients Diagnosed with Multiple Myeloma Integrating Frailty Screening for Older Patients Diagnosed with Multiple Myeloma Target Audience This activity has been designed to meet the educational needs of hematologists, medical oncologists, physician

More information

INTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY

INTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY INTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY LM Pérez (1), P Burbano (1), M Hernandez (1), N Gual (1,2), G Liesa (1), E Martin (3), L Tobella (3), MB Enfedaque

More information

HEART INTERVENTIONS IN OLDER PATIENTS. FILTERING FOR FRAILTY.

HEART INTERVENTIONS IN OLDER PATIENTS. FILTERING FOR FRAILTY. HEART INTERVENTIONS IN OLDER PATIENTS. FILTERING FOR FRAILTY. December 8, 2017 Allen R. Huang, MDCM, FRCPC, FACP 1 Faculty Disclosure Faculty: Allen Huang MDCM, FRCPC, FACP Associate Professor, University

More information

Comorbidities and cancer Applications to non small cell lung cancer

Comorbidities and cancer Applications to non small cell lung cancer Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 July 2003 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION

More information

Pre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014

Pre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014 Pre- Cardiac intervention Frailty assessment Dr. Victor Sim 26 th Sept 2014 Defining frailty Lacks consensus (Rockwood CMAJ 2005;173(5):489-95 Introduction) Some consider symptoms, signs, diseases and

More information

Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham

Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without

More information

Oncology Highlights ASCO 2011 MULTIPLE MYELOMA

Oncology Highlights ASCO 2011 MULTIPLE MYELOMA Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures

More information

Myeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania

Myeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline

More information

Role of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands

Role of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:

More information

Approach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic

Approach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of

More information

Michel Delforge Belgium. New treatment options for multiple myeloma

Michel Delforge Belgium. New treatment options for multiple myeloma Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide

More information

Definitions in Palliative Care

Definitions in Palliative Care Definitions in Palliative Care Palliative care is specialist care provided for all people living with, and dying from a terminal condition and for whom the primary goal is quality of life. Palliative Care

More information

Comprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies

Comprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies BHSSeminar#7 Generalskills Comprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies Prof.&&&Dominique&&BRON& Inst.&J.&Bordet&&7&ULB& 24th&of&May&2014& 1 WHY WHEN HOW WhyCGA?!

More information

DRAFT FOR PUBLIC CONSULTATION

DRAFT FOR PUBLIC CONSULTATION SEE MYELOMA ELIGIBLE egfr < 30ml/min Multiple myeloma despite correction of hypercalcaemia and dexamethasone? Yes Transplant eligible? Yes SEE MYELOMA- RENAL SEE MYELOMA INELIGIBLE KEY Click to move to

More information

IMiDs (Immunomodulatory drugs) and Multiple Myeloma

IMiDs (Immunomodulatory drugs) and Multiple Myeloma www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com

More information

Old age, polymorbidity and stroke, a new epidemy?

Old age, polymorbidity and stroke, a new epidemy? Old age, polymorbidity and stroke, a new epidemy? Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals Visiting Professor

More information

Highlights from EHA Mieloma Multiplo

Highlights from EHA Mieloma Multiplo Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :

More information

Managing Newly Diagnosed Multiple Myeloma

Managing Newly Diagnosed Multiple Myeloma Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB

More information

Frailty as deficit accumulation

Frailty as deficit accumulation Frailty as deficit accumulation Kenneth Rockwood MD, FRCPC, FRCP Division of Geriatric Medicine Dalhousie University & Capital District Health Authority Halifax, Canada Read it as: Rockwood K, Mitnitski

More information

To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York

To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance

More information

which to base economic assessment of the products available to treat this hematologic

which to base economic assessment of the products available to treat this hematologic special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis

More information

Background Information

Background Information What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome

More information

How to Integrate the New Drugs into the Management of Multiple Myeloma

How to Integrate the New Drugs into the Management of Multiple Myeloma How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients

More information

Frailty: Challenges and Possible Solutions

Frailty: Challenges and Possible Solutions Frailty: Challenges and Possible Solutions EMA Workshop: Ensuring safe and effective medicines for an ageing population Niccolò Marchionni Professor of Geriatrics University of Florence, Italy 22-23 March

More information

Problems related to the management of malignant hemopathies in older patients

Problems related to the management of malignant hemopathies in older patients Problems related to the management of malignant hemopathies in older patients Dr Marie Maerevoet Gent, 25 January 2013 BHS satellite symposium on Elderly Malignant Hemopathies in older patients - 33% of

More information

Induction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program

Induction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification

More information

MULTIPLE MYELOMA AFTER AGE OF 80 YEARS

MULTIPLE MYELOMA AFTER AGE OF 80 YEARS MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et

More information

Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study

Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure

More information

Practical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors

Practical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer

More information

Interprofessional Care for Elders through 48/5

Interprofessional Care for Elders through 48/5 Interprofessional Care for Elders through 48/5 Janet E. McElhaney, MD, FRCPC, FACP HSN Volunteer Association Chair in Geriatric Research Professor of Medicine, Northern Ontario School of Medicine Health

More information

How I Treat Transplant Eligible Myeloma Patients

How I Treat Transplant Eligible Myeloma Patients How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM

More information

Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael

More information

Unintentional Weight Loss. Prof. G. Zuliani

Unintentional Weight Loss. Prof. G. Zuliani Unintentional Weight Loss Prof. G. Zuliani Is weight loss clinically important? Definition Clinically important weight loss can be defined as loss of >5 kg, or >5% of usual weight over a period of 3 months,

More information

Frailty in Older Adults

Frailty in Older Adults Frailty in Older Adults John Puxty puxtyj@providencecare Geriatrics 20/20: Bringing Current Issues into Perspective Session Overview Definition of Frailty Strategies for identifying frail older adults

More information

Specialist Palliative Care Service Referral Criteria and Guidance

Specialist Palliative Care Service Referral Criteria and Guidance Specialist Palliative Care Service Referral Criteria and Guidance Specialist Palliative Care Service Referrals These guidelines cover referrals for patients with progressive terminal illness, whether

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old

More information

Dana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3

Dana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3 The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study

More information

Biological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD

Biological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD Biological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD World Health Organization Geneva (Switzerland) December 1, 2016 World Health Organization.

More information

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma October 1, 2015

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma October 1, 2015 pan-canadian Oncology Drug Review Initial Clinical Guidance Report Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma October 1, 2015 DISCLAIMER Not a Substitute for Professional Advice This

More information

Community and Mental Health Services. Palliative Care. Criteria and

Community and Mental Health Services. Palliative Care. Criteria and Community and Mental Health Services Specialist Palliative Care Service Referral Criteria and Guidance November 2018 Specialist Palliative Care Service Referrals These guidelines cover referrals for patients

More information

The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly

The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly ORIGINAL ARTICLE Korean J Intern Med 2016;31:594-600 The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly Hee-Won Jung 1,2, Hyun-Jung

More information

Integrating Geriatrics into Oncology Care

Integrating Geriatrics into Oncology Care Integrating Geriatrics into Oncology Care William Dale, MD, PhD Chief, Geriatrics & Palliative Medicine Director, Specialized Oncology Care & Research in the Elderly (SOCARE) Clinic University of Chicago

More information

Nutritional Assessment in frail elderly. M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze

Nutritional Assessment in frail elderly. M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze Nutritional Assessment in frail elderly M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze Frailty definition Undernutrition as part of the frailty syndrome Nutritional assessment in frail

More information

Current Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.

Current Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene

More information

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,

More information

AHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.

AHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1. AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible

More information

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015 Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the

More information

Frailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa

Frailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa Frailty Nicholas Butler MD, MBA Department of Family Medicine University of Iowa Doris 84 yo female who comes into your clinic with her daughter. She complains of feeling increasingly fatigued and just

More information

Specialist Palliative Care Referral for Patients

Specialist Palliative Care Referral for Patients Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages

More information

Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma

Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information

More information

The role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano

The role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano The role of liposomal doxorubicin in DLBCL lymphomas Michele Spina Aviano Disclosures of Michele Spina Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other

More information

What is frailty and why it is important

What is frailty and why it is important What is frailty and why it is important Tony Moran North West Knowledge and Intelligence Team Cancer Outcomes Conference 2013 Contents Definitions of frail and frailty Prevalence and measurement Use in

More information

Welcome to the Routine frailty identification in the GP contract webinar presented by Dawn Moody

Welcome to the Routine frailty identification in the GP contract webinar presented by Dawn Moody Welcome to the Routine frailty identification in the GP contract webinar presented by Dawn Moody The presentation will begin at 12.00pm. Attendees will be muted during the presentation to avoid interference.

More information

Multiple Myeloma: Induction, Consolidation and Maintenance Therapy

Multiple Myeloma: Induction, Consolidation and Maintenance Therapy Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of

More information

Methods: Studies included in the analysis

Methods: Studies included in the analysis Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,

More information

Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile?

Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31

More information

37 Novel Therapies for

37 Novel Therapies for 37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different

More information

FRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger

FRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger FRAILTY SYNDROME dr. Rose Dinda Martini, Sp.PD, K-Ger Geriatric Division, Internal Medicine Department M. Djamil Hospital Padang Faculty of Medicine, Andalas University, 2018 Medical syndrome Multiple

More information

Frailty as deficit accumulation

Frailty as deficit accumulation Frailty as deficit accumulation Kenneth Rockwood MD, FRCPC, FRCP Division of Geriatric Medicine Dalhousie University & Capital District Health Authority Halifax, Canada Read it as: Rockwood K, Mitnitski

More information